Abstract: A display substrate includes at least two barrier layers in a peripheral area of the display substrate. The at least two barrier layers includes a first barrier layer forming an enclosure; and a third barrier layer on a side of the first barrier layer closer to a display area. The third barrier layer includes one or more discontinuous portions.

Abstract: A jet flow adjustment method for rotary steerable downhole release includes steps of: defining a diversion ratio p of a jet nozzle by a ground control system; and sending the diversion ratio p of the jet nozzle to a control unit of a downhole rotary steerable system; and determining an opening areas of the jet nozzle by the control unit according to the diversion ratio p of the jet nozzle and an equivalent channel area S of a drilling tool; controlling an adjustable bypass valve by the control unit of the downhole rotary steerable system according to the calculated opening area s of the jet nozzle, so as to control an overlapping area between sector holes of a rotor end and a stator end, thereby opening the jet nozzle for release. The present invention has simple control and strong release ability.

Abstract: A fuel supply apparatus for a fuel cell system, the apparatus comprising a manifold unit comprising a body; a fuel supply flow path by which fuel is supplied to an inlet of said fuel cell system, the fuel supply flow path extending at least partly through the body of the manifold unit; a fuel recirculation flow path by which residual fuel is transferred from an outlet of said fuel cell system to the fuel supply flow path, the fuel recirculation flow path extending at least partly through the body of the manifold unit; at least one valve for controlling flow along the fuel supply flow path and/or the fuel recirculation flow path, wherein the at least one valve is integral to the body of the manifold unit; and a heating apparatus, wherein at least a heating portion of the heating apparatus is integral to the body of the manifold unit.

Abstract: Provided is a display substrate. The display substrate includes: a display region and a bonding region on a side of the display region, wherein the display region includes a plurality of pixel columns; and a wiring structure, disposed between the display region and the bonding region and including a plurality of traces, wherein one of the plurality of traces corresponds to one of the plurality of pixel columns, the plurality of traces are electrically connected to the plurality of pixel columns to supply an electric signal to pixels, and each of the plurality of traces includes a plurality of sub-traces, wherein at least one of line lengths and line widths of sub-traces corresponding to at least a part of the plurality of traces are different, such that total resistances of the at least the part of the plurality of traces are basically equal.

Abstract: A display substrate includes a base substrate, multiple sub-pixels, multiple first gate drive circuits, and at least one auxiliary structure. The base substrate includes a display region and a peripheral region located at a periphery of the display region. The multiple sub-pixels are located in the display region. The multiple first gate drive circuits and the at least one auxiliary structure are located in the peripheral region. The multiple first gate drive circuits are configured to provide first gate drive signals to the multiple sub-pixels. One auxiliary structure is disposed between adjacent first gate drive circuits.

Abstract: Provided are a fusion protein and a medical use thereof. The fusion protein is prepared by fusing a human interleukin-10 (IL-10) with an Fc fragment of an immunoglobulin IgG via a linker peptide. The Fc fragment is the Fc fragment of human IgGI, human IgG2 and human IgG4, and the human interleukin-10 includes an amino acid sequence as shown in SEQ ID NO: 1. The fusion protein may be used for the treatment of immunological diseases and cancers, and prolongs the in vivo half-life of human IL-10 and increases the in vivo stability of human IL-10.

Abstract: The present invention provides an artificial dressing and a use of the artificial dressing for promoting wound healing. The artificial dressing includes a gelatin and a fungal extract.

Abstract: The present application relates to the field of biomedicine, and particularly provides an anti-LAG-3 monoclonal antibody and an antigen binding fragment thereof, and use thereof, wherein the anti-LAG-3 monoclonal antibody and the antigen binding fragment thereof comprise a heavy chain variable region and a light chain variable region, and are selected from any one of A-1, A-2: A-3, and A-4.

Abstract: Disclosures of the present invention describe a double-layer dressing containing silk fibroin and a method for making the same, wherein the double-layer dressing mainly comprises a silk fibroin layer and a calcium-degradation silk fibroin layer connected to the silk fibroin layer, and it is worth emphasizing that, results of animal experiment have proved that this novel double-layer dressing is an outstanding hemostatic wound dressing; Moreover, additional adhesion, resulted from the solidification of tissue fluid, can be effectively prevented from forming between skin wound and wound dressing under the use of this double-layer dressing.

Abstract: The present disclosure provides a method of measuring a plurality of voids in an underfill material of an underfill package. The method includes operations of obtaining a welding angle profile of the underfill package; obtaining a simulated void profile of the underfill package according to the welding angle profile; determining a plurality of high-risk void regions according to the simulated void profile; simulating, according to a selected pressure and a selected temperature of the underfill material, a first high-risk void region of the plurality of high-risk void regions to generate an updated void profile; and determining whether the updated void profile meets a void requirement of the underfill package.

Abstract: An anti-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.

Abstract: The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened.

Abstract: The application belongs to the technical field of biomedicines and provides an improved anti-Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library is designed, and an improved anti-VEGFR-2 monoclonal antibody is obtained after multiple rounds of screening. Both affinity and biological activity of the antibody are higher than those of an original antibody. The antibody is capable of effectively inhibiting combination of VEGFR-2 and a ligand Vascular Endothelial Growth Factor (VEGF) thereof in vitro, and may be used in treating a tumor and a disease caused by angiogenesis such as macular degeneration.

Abstract: An art-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.

Abstract: The application discloses an anti-Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) monoclonal antibody, an amino acid sequence comprising coded antibody variable regions and Complementarity-Determining Regions (CDR), the obtaining method, and application of monoclonal antibody. The anti-PCSK9 monoclonal antibodies are screened from a phage antibody library; affinity maturation is achieved by using a method that the phage antibody library is established by means of chain displacement; After screening the light chain CDR1, 2, 3 Mutant Library of monoclonal antibodies obtained from primary screening; monoclonal antibodies having high affinity are selected; then screening the mutant libraries of heavy chain CDR1, 2, 3 regions; and finally the monoclonal antibodies having high affinity are screened.

Abstract: Provided is a method of making a fiber comprising metal nanoparticles. The method includes steps of: Step (A): providing a fiber and a metal salt aqueous solution comprising first metal ions; Step (B): making the metal salt aqueous solution contact the fiber to form a fiber containing the first metal ions; and Step (C): contacting the fiber containing the first metal ions with a second metal, and performing a reduction reaction of the first metal ions to obtain the fiber comprising metal nanoparticles, wherein the fiber comprising metal nanoparticles comprises first metal nanoparticles from a reduction of the first metal ions; wherein a standard reduction potential of the first metal ions is greater than a standard reduction potential of an ionic state of the second metal, and a difference therebetween ranges from 0.4 V to 4.0 V.

Abstract: The application belongs to the technical field of biomedicines and provides an improved anti-Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) monoclonal antibody and an application thereof. By a computer-aided simulation design, a novel phage antibody library is designed, and an improved anti-VEGFR-2 monoclonal antibody is obtained after multiple rounds of screening. Both affinity and biological activity of the antibody are higher than those of an original antibody. The antibody is capable of effectively inhibiting combination of VEGFR-2 and a ligand Vascular Endothelial Growth Factor (VEGF) thereof in vitro, and may be used in treating a tumor and a disease caused by angiogenesis such as macular degeneration.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: Disclosures of the present invention describe a double-layer dressing containing silk fibroin and a method for making the same. The double-layer dressing mainly comprises a silk fibroin layer and a calcium-degradation silk fibroin layer connected to the silk fibroin layer. It is worth emphasizing that, results of animal experiment have proved that this novel double-layer dressing is an outstanding hemostatic wound dressing. Moreover, additional adhesion, resulted from the solidification of tissue fluid, can be effectively prevented from forming between skin wound and wound dressing under the use of this double-layer dressing.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.